# Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children

> **NCT00307021** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 180 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049

## Key facts

- **NCT ID:** NCT00307021
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-07
- **Primary completion:** 2006-09-15
- **Final completion:** 2007-08-22
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00307021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00307021, "Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00307021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*